

1. [Sanofi, Boehringer Ingelheim seek CCI nod for \\$25-billion global asset swap deal](#) - **The Economic Times**

European drug giants Sanofi and Boehringer Ingelheim (BI) have filed with the Competition Commission of India for local regulatory clearances that form part of their recently announced global asset swap deal worth \$25 billion. The transaction, when completed, will see the \$41 billion Sanofi take over Boehringer Ingelheim's consumer healthcare business, excluding China. In exchange, the French drug maker will transfer Merial, its global animal healthcare business, to the family-owned German pharmaceutical group.

2. [Piramal Fund invests Rs 200 crore in Prateek Edifice project](#) - **The Economic Times**

Piramal Fund Management has invested Rs 200 crore in a residential project of Noida-based builder Prateek Group. The ultra-luxurious residential project, Prateek Edifice, located in Noida's

sector 107, is in the midst of construction. "The partners have entered into a strategic relation recently and plan to extend it in future," a person aware of the transaction said on condition of anonymity.

3. [Health ministry asks states to cap prices of dengue tests](#) - **ET Healthworld.com**

To protect patients from being overcharged by private laboratories and hospitals, the health ministry has asked all states to cap prices of dengue tests. The decision was taken in a review meeting headed by health minister JP Nadda on Friday to assess the preparedness and measures taken by the Centre as well as states to tackle the outbreak of dengue.

4. [India's pharma industry expected to grow to \\$55 bn by 2020](#) - **ET Healthworld.com**

India's rapidly growing pharmaceutical market is expected to grow to \$55 billion by 2020 and emerge as the sixth largest globally by size, said Indian Ambassador to the US Arun Singh. Formally inaugurating the 34th annual convention of the American Association of Physicians of Indian Origin (AAPI) here Friday, he outlined the rapid growth of the health sector in India, particularly in pharmaceuticals.

1. [Sanofi, Boehringer Ingelheim seek CCI nod for \\$25-billion global asset swap deal](#) - The Economic Times
2. [Piramal Fund invests Rs 200 crore in Prateek Edifice project](#) - The Economic Times
3. [Health ministry asks states to cap prices of dengue tests](#) - ET Healthworld.com
4. [India's pharma industry expected to grow to \\$55 bn by 2020](#) - ET Healthworld.com
5. [UK drugs regulator to halt approvals for clinical trials firm Quest Life Sciences](#) - Mint
6. [Dr Reddy's to have stronger quality system by 2016-end: G V Prasad](#) - Business Standard
7. [Why India needs a Ministry of Public Health](#) - The Times of India
8. [What is the real challenge of FDI Policy in India?](#) - Deccan Herald
9. [Biocon's future bets are on biosimilars](#) - The New Indian Express
10. [Jan Aushadhi Kendras to come up in taluks and PHCs](#) - The Hindu
11. [New Breakthrough in TB treatment](#) - Bangalore Mirror
12. [Kerala govt soon to initiate steps for establishing pharma park in the state](#) - Pharmabiz.com
13. [AIOCD to go on indefinite shut down by July end if govt fails to meet its demands](#) - Pharmabiz.com

5. [UK drugs regulator to halt approvals for clinical trials firm Quest Life Sciences](#) – Mint
The UK's healthcare regulator has decided to suspended marketing approval for a widely used antibiotic that had won clearance based on clinical trials conducted by India's Quest Life Sciences Pvt. Ltd, due to concerns over the integrity of trial data. The Medicines and Healthcare products Regulatory Agency (MHRA) might also deny other pending drug approval requests that rely on studies conducted by Quest, the UK agency said in a letter dated 22 June, a copy of which was seen by Reuters.
6. [Dr Reddy's to have stronger quality system by 2016-end: G V Prasad](#) – Business Standard
Indian pharmaceutical major Dr Reddy's Laboratories Limited said it will have a stronger quality system in place by the end of this year. This comes in the backdrop of the remediation efforts launched by the company after the US Food and Drug Administration (USFDA) issued a warning letter over certain compliance issues last year.
7. [Why India needs a Ministry of Public Health](#) – The Times of India
In an authored article, member of Health Task Force, DDMA, Government of Karnataka & CEO, Center for Health and Development, Mangaluru, Edmond Fernandes talks about how the present government needs to invest heavily in healthcare. Budget allocations for healthcare is a signal that the Ministry has no serious intention to change the trends. Sloganeering and rhetoric cannot be good governance, which as a concept is very deep and serious. Another joke as a country is that we have people with law background running health ministries. The competency of such individuals calls for serious questioning. These are internal challenges which we can easily correct, yet refuse too.
8. [What is the real challenge of FDI Policy in India?](#) – Deccan Herald
Dinesh Abrol, Professor, Institute for Studies in Industrial Development (ISID), highlights the different aspects of FDI policy for pharmaceutical industry. The Central Government's decision to allow up to 74% FDI as brownfield investment in pharmaceutical companies through the automatic route has serious implications for the industry as well as the people. On the R&D productivity crisis he says, Foreign firms are interested to kill the problem of potential competition from the domestic firms from the roots. Their profitability has been falling due to the growing R&D productivity crisis emerging from their faulty business model and strong intellectual property driven R&D organisation. Highlighting the transparent conditionality of the policy, he says, the FDI policy should introduce a clear and transparent conditionality that will compulsorily all the brownfield investors to undertake 'greenfield foreign investment' of a matching amount for the purpose of expansion of activities of 'production and innovation' to be undertaken from the basic stage in concerned company. The policy of 74% share of FDI to the foreign investor and the remaining with locals does not attend to the issue of participation of the local investors in the company operations.
9. [Biocon's future bets are on biosimilars](#) – The New Indian Express
BENGALURU-based biopharma Biocon Ltd during the annual general meeting on Friday, said, it is banking on four of its advanced programmes to play a major role at the global level. Biocon Chairperson Kiran Mazumdar-Shaw said that the biosimilars are for treating cancer, diabetes and psoriasis. Mazumdar-Shaw said, "Regulatory filings for four most-advanced biosimilar programmes -- Insulin Glargine, Trastuzumab, Pegfilgrastim and Adalimumab - are likely to provide us an early-mover advantage in an over \$30 billion addressable market."
10. [Jan Aushadhi Kendras to come up in taluks and PHCs](#) – The Hindu
"The Karnataka State government will consider opening Jan Aushadhi Kendras in taluks and at primary health care centres to allow patients to buy generic medicines at subsidised prices," Eshwar B. Khandre, Minister of State for Municipal Administration, said here on Sunday. He was speaking after inaugurating a Kendra at the district hospital, the second such outlet in the State and the first in Hyderabad Karnataka.

11. [New Breakthrough in TB treatment](#) – Bangalore Mirror

In a major breakthrough, researchers of the Indian Institute of Science (IISc), Bengaluru, have identified a protein - Rv1860 - which can stimulate protective immunity against tuberculosis (TB). According to the research team, immune responses to this protein are distinctly different in healthy people when compared to TB patients. This finding will enable doctors to predict whether a patient undergoing the painfully long-duration TB treatment is responding to the drugs. These findings also have the potential to strengthen the existing BCG (Bacille Calmette-Guerin vaccine).

12. [Kerala govt soon to initiate steps for establishing pharma park in the state](#) – Pharmabiz.com

The Kerala government will soon initiate steps for materializing the demand of the state pharma industry and allied sectors for establishing a comprehensive pharma park in the state, according to government sources. According to sources, the government has now asked KINFRA, the nodal agency for implementing the project, to identify the area and it has found the suitable land in Kannur district. Sources said that 40 acres of land was identified in Kannur district and it is an ideal place for the industrial cluster set up. However, the industry sources say that an area of 40 acres of land is not suitable for a comprehensive cluster for the pharma industry in the state. Kerala has more than 90 pharma manufacturing units and about 1000 marketing companies.

13. [AIOCD to go on indefinite shut down by July end if govt fails to meet its demands](#) – Pharmabiz.com

All India Organisation of Chemists and Druggists (AIOCD) has decided to go on indefinite strike by the end of this month if the government fails to comply with their demands that include a ban on online pharmacy, directing drug companies to provide revised price list of drugs as per wholesale price index (WPI) as well as taking action against pharma companies supplying banned fixed dose combination drugs in the market under the garb of Delhi High Court's stay order. Last year AIOCD held a day-long bandh to protest against illegal online sale of medicine. The Bombay High Court also ordered the government to check sale of drugs online. While online pharmacy business continues to operate illegally, the government authorities concerned are not taking any action despite several complaints made by the AIOCD, he rued. Despite several appeals, the government has not initiated steps to resolve issues pertaining to online pharmacy, FDCs and WPA, he opined. Hence AIOCD had passed a resolution at a meeting held in Hyderabad on June 24-25 to go on indefinite strike by the end of this month if the government fails to meet their demands, Gupta concluded.